An Open-Label Extension Study to Assess the Long-Term Efficacy and Safety of a Plasma-Derived von Willebrand Factor (VWF)/Factor VIII (FVIII) Concentrate in Patients with von Willebrand Disease (SWIFT-VWDext Study).

导出 LinkOut

翻译打印收藏纠错

作者： Toshko,Lissitchkov ^[1] ; Anna,Klukowska ^[2] ; Evgeny,Buevich ^[3] ; Irina,Maltceva ^[3] ; Guenter,Auerswald ^[4] ; Oleksandra,Stasyshyn ^[5] ; Wilfried,Seifert ^[6] ; Tobias,Rogosch ^[6]

作者单位： Specialized Hospital for Active Treatment (SHAT), Sofia, Bulgaria. ^[1] Department of Paediatrics, Haematology and Oncology of Warsaw Medical University, Warsaw, Poland. ^[2] GOUVPO Altaysky State Medical University of Roszdrav, Bernaul, Russian Federation. ^[3] Prof. Hess Kinderklinik, Klinikum Bremen-Mitte, Bremen, Germany. ^[4] Institute of Pathology and Transfusion Medicine AMN, Lviv, Ukraine. ^[5] Clinical Development, CSL Behring, Marburg, Germany. ^[6]

关键词 hemostatic efficacy on-demand prophylaxis safety surgery von Willebrand disease

DOI 10.2147/JBM.S268907

PMID 33117020

发布时间 2022-04-17

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Journal of blood medicine

2020年11卷

345-356页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

An Open-Label Extension Study to Assess the Long-Term Efficacy and Safety of a Plasma-Derived von Willebrand Factor (VWF)/Factor VIII (FVIII) Concentrate in Patients with von Willebrand Disease (SWIFT-VWDext Study).

Journal of blood medicine

相似文献

Journal of blood medicine

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

An Open-Label Extension Study to Assess the Long-Term Efficacy and Safety of a Plasma-Derived von Willebrand Factor (VWF)/Factor VIII (FVIII) Concentrate in Patients with von Willebrand Disease (SWIFT-VWDext Study).

Journal of blood medicine

相似文献

Journal of blood medicine

相关期刊

检索历史清除